Fecal ESBL Resurgence During Antibiotic Treatment

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03206879

Enrollment

Registered

2017-07-02

Start date

2016-11-30

Completion date

2018-12-31

Last updated

2024-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Antibiotic Drug Resistance

Keywords

ESBL, Enterobacteriaceae, multidrug-resistance

Brief summary

Norwegian hospitals are struggling to control spread of extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBL-E) in health care settings. Strict screening and isolation criteria are enforced in hospital, and patients previously infected by ESBL-E are regarded as possible ESBL-E carriers indefinitely. This observational multi-centre cross-sectional study aims to estimate the duration of fecal ESBL-E carriage and to assess the risk of ESBL-E resurgence during hospital stay for patients previously infected by ESBL-E. Through better knowledge of these risk factors, infection control procedures may be better tailored to rhe individual patient.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 120 Years

Healthy volunteers

Inclusion criteria

Patients with previous infection or colonization with ESBL-E admitted to one of the participating wards. -

Exclusion criteria

* Not able to give informed consent.

Design outcomes

Primary

Measure	Time frame
fecal carriage of ESBL-E	Baseline

Secondary

Measure	Time frame
fecal ESBL-E carriage developed during admission	Baseline (admission)

Outcome results